Individualized survival prediction for patients with oropharyngeal cancer in the human papillomavirus era

Accurate, individualized prognostication in patients with oropharyngeal squamous cell carcinoma (OPSCC) is vital for patient counseling and treatment decision making. With the emergence of human papillomavirus (HPV) as an important biomarker in OPSCC, calculators incorporating this variable have been developed. However, it is critical to characterize their accuracy prior to implementation.

[1]  Yilun Sun,et al.  Individualized risk prediction of outcomes for oral cavity cancer patients. , 2016, Oral oncology.

[2]  C. West,et al.  Dynamic contrast-enhanced magnetic resonance imaging biomarkers in head and neck cancer: potential to guide treatment? A systematic review. , 2014, Oral oncology.

[3]  H. Sudhoff,et al.  De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. , 2014, European journal of cancer.

[4]  B. O'Sullivan,et al.  Overview of the 8th Edition TNM Classification for Head and Neck Cancer , 2017, Current Treatment Options in Oncology.

[5]  W. Grolman,et al.  Prognostic value of continued smoking on survival and recurrence rates in patients with head and neck cancer: A systematic review , 2016, Head & neck.

[6]  Brian O'Sullivan,et al.  Head and neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[7]  C. Metz.  Basic principles of ROC analysis. , 1978, Seminars in nuclear medicine.

[8]  Lauren J. Beesley,et al.  Individualized outcome prognostication for patients with laryngeal cancer , 2018, Cancer.

[9]  Kenneth L Kehl,et al.  Association of Actual and Preferred Decision Roles With Patient-Reported Quality of Care: Shared Decision Making in Cancer Care. , 2015, JAMA oncology.

[10]  Jeremy M G Taylor,et al.  EM algorithms for fitting multistate cure models. , 2019, Biostatistics.

[11]  P. Heagerty,et al.  Survival Model Predictive Accuracy and ROC Curves , 2005, Biometrics.

[12]  R. Lilford,et al.  Are randomized clinical trials good for us (in the short term)? Evidence for a "trial effect". , 2001, Journal of clinical epidemiology.

[13]  E. Dronkers,et al.  Influence of anemia and BMI on prognosis of laryngeal squamous cell carcinoma: Development of an updated prognostic model. , 2018, Oral oncology.

[14]  S. Fosså,et al.  Selection of Patients may Limit the Generalizability of Results from Cancer Trials , 2002, Acta oncologica.

[15]  B. Conley,et al.  Bridging the Gap: Moving Predictive and Prognostic Assays from Research to Clinical Use , 2012, Clinical Cancer Research.

[16]  J. Shah,et al.  HPV-Mediated (p16+) Oropharyngeal Cancer , 2017 .

[17]  L. Sobin,et al.  TNM: evolution and relation to other prognostic factors. , 2003, Seminars in surgical oncology.

[18]  P. Lambin,et al.  Externally validated HPV-based prognostic nomogram for oropharyngeal carcinoma patients yields more accurate predictions than TNM staging. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  Esther Kim,et al.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Marc P van der Schroeff,et al.  Impact of comorbidity on short‐term mortality and overall survival of head and neck cancer patients , 2009, Head & neck.

[21]  Ruud H. Brakenhoff,et al.  The molecular landscape of head and neck cancer , 2018, Nature Reviews Cancer.

[22]  E. Karapanagiotou,et al.  Head and neck cancer in the elderly: an overview on the treatment modalities. , 2009, Cancer treatment reviews.

[23]  J. Piccirillo,et al.  Update and external validation of a head and neck cancer prognostic model , 2013, Head & neck.

[24]  D. Stacey,et al.  Exploring cancer treatment decision-making by patients: a descriptive study. , 2010, Current oncology.

[25]  Jeremy M G Taylor,et al.  Cigarette use, comorbidities, and prognosis in a prospective head and neck squamous cell carcinoma population , 2016, Head & neck.

[26]  D. Hayes,et al.  Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Shao Hui Huang,et al.  Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. , 2016, The Lancet. Oncology.

[28]  D. Hayes,et al.  Mature results of a prospective study of deintensified chemoradiotherapy for low‐risk human papillomavirus‐associated oropharyngeal squamous cell carcinoma , 2018, Cancer.

[29]  Cary P Gross,et al.  NCI SEER public-use data: applications and limitations in oncology research. , 2009, Oncology.

[30]  G. Wolf,et al.  Interleukin‐6 predicts recurrence and survival among head and neck cancer patients , 2008, Cancer.

[31]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.

[32]  J. Mandrekar.  Receiver operating characteristic curve in diagnostic test assessment. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[34]  K. Wong,et al.  Refining risk stratification for locoregional failure after chemoradiotherapy in human papillomavirus-associated oropharyngeal cancer. , 2014, Oral oncology.

[35]  L. Squiers,et al.  Implementing and evaluating shared decision making in oncology practice , 2014, CA: a cancer journal for clinicians.

[36]  James R Carpenter,et al.  Multiple imputation of covariates by fully conditional specification: Accommodating the substantive model , 2012, Statistical methods in medical research.

[37]  C. von Buchwald,et al.  Human Papillomavirus Shows Highly Variable Prevalence in Esophageal Squamous Cell Carcinoma and No Significant Correlation to p16INK4a Overexpression: A Systematic Review , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  Christopher U. Jones,et al.  Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  H. Dienes,et al.  Combined analysis of HPV‐DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer , 2007, International journal of cancer.

[40]  C. Chung,et al.  E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  James W Dearing,et al.  Predicting Cancer Prognosis Using Interactive Online Tools: A Systematic Review and Implications for Cancer Care Providers , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[42]  Susan Halabi,et al.  American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine , 2016, CA: a cancer journal for clinicians.

[43]  W. Hong,et al.  Head and Neck Cancer: A Multidisciplinary Approach , 2013 .

[44]  John Cho,et al.  Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  C. von Buchwald,et al.  Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer: a population-based study of 1,542 consecutive patients , 2016, Oncotarget.

[46]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[47]  Mithat Gonen,et al.  Nomograms in oncology: more than meets the eye. , 2015, The Lancet. Oncology.

[48]  R. Amdur,et al.  Current Status and Future Directions of Treatment Deintensification in Human Papilloma Virus-associated Oropharyngeal Squamous Cell Carcinoma. , 2018, Seminars in radiation oncology.